Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients
Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of
Agenus tested a cancer treatment on very sick patients. About half of them lived three years, which looks promising for this hard-to-treat disease.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.